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Dendrimers are nano-sized, radially symmetric molecules with well-defined, homogeneous, and monodisperse structure
that has a typically symmetric core, an inner shell, and an outer shell. Their three traditional macromolecular architectural
classes are broadly recognized to generate rather polydisperse products of different molecular weights. A variety
of dendrimers exist, and each has biological properties such as polyvalency, self-assembling, electrostatic interactions,
chemical stability, low cytotoxicity, and solubility. These varied characteristics make dendrimers a good choice in the
medical field, and this review covers their diverse applications.
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Introduction
Dendrimers are nano-sized, radially symmetric molecules
with well-defined, homogeneous, and monodisperse struc-
ture consisting of tree-like arms or branches [1]. These
hyperbranched molecules were first discovered by Fritz
Vogtle in 1978, by Donald Tomalia and co-workers in
the early 1980s, and at the same time, but independ-
ently by George R. Newkome. The second group called
synthesized macromolecules ‘arborols’ means, in Latin,
‘trees’. Dendrimers might also be called ‘cascade mole-
cules’, but this term is not as much established as ‘den-
drimers’ [2-4]. Dendrimers are nearly monodisperse
macromolecules that contain symmetric branching units
built around a small molecule or a linear polymer core
[5-7]. ‘Dendrimer’ is only an architectural motif and not a
compound. Polyionic dendrimers do not have a persistent
shape and may undergo changes in size, shape, and
flexibility as a function of increasing generations [8-10].
Dendrimers are hyperbranched macromolecules with a
carefully tailored architecture, the end-groups (i.e., the
groups reaching the outer periphery), which can be
functionalized, thus modifying their physicochemical or
biological properties [11-16]. Dendrimers have gained a* Correspondence: Akbarzadehab@tbzmed.ac.ir; tayefih@yahoo.com; Swjoo@
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in any medium, provided the original work is pbroad range of applications in supramolecular chemistry,
particularly in host-guest reactions and self-assembly pro-
cesses. Dendrimers are characterized by special features
that make them promising candidates for a lot of applica-
tions. Dendrimers are highly defined artificial macromole-
cules, which are characterized by a combination of a high
number of functional groups and a compact molecular
structure [17]. The emerging role of dendritic macromole-
cules for anticancer therapies and diagnostic imaging is re-
markable. The advantages of these well-defined materials
make them the newest class of macromolecular nano-
scale delivery devices [18]. Dendritic macromolecules tend
to linearly increase in diameter and adopt a more globular
shape with increasing dendrimer generation. Therefore,
dendrimers have become an ideal delivery vehicle candi-
date for explicit study of the effects of polymer size,
charge, and composition on biologically relevant proper-
ties such as lipid bilayer interactions, cytotoxicity, intern-
alization, blood plasma retention time, biodistribution,
and filtration [19] (Figure 1).Structure and chemistry
The structure of dendrimer molecules begins with a cen-
tral atom or group of atoms labeled as the core. From
this central structure, the branches of other atoms called
‘dendrons’ grow through a variety of chemical reactions.
There continues to be a debate about the exact structure
of dendrimers, in particular whether they are fully ex-
tended with maximum density at the surface or whether
the end-groups fold back into a densely packed interiorn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Figure 1 Schematic representation of a generation G4 dendrimer with 64 amino groups at the periphery. This dendrimer starts from an
ethylene diamine core; the branches or arms were attached by exhaustive Michael addition to methyl acrylate followed by exhaustive aminolysis
of the resulting methyl ester using ethylene diamine [20].
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trol not attainable with most linear polymers, leading to
nearly monodisperse, globular macromolecules with a
large number of peripheral groups as seen in Figure 2, the
structure of some dendrimer repeat units, for example,
the 1,3-diphenylacetylene unit developed by Moore [23].Figure 2 Types of dendrimers. (A) More type dendrimers consisting of p
dwell in the same space, and the fourth-generation layer potential overlap
chiral, non-racemic, and with intramolecular folding driven by hydrogen boDendrimers are a new class of polymeric belongings.
Their chemistry is one of the most attractive and hastily
growing areas of new chemistry [25-27]. Dendrimer
chemistry, as other specialized research fields, has its
own terms and abbreviations. Furthermore, a more brief
structural nomenclature is applied to describe thehenyl acetylene subunits at the third-generation different arms may
s with the second-generation layer. (B) Parquette-type dendrons are
nding [24].
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surface. Dendrigrafts are a class of dendritic polymers
like dendrimers that can be constructed with a well-
defined molecular structure, i.e., being monodisperse [28].
The unique structure of dendrimers provides special op-
portunities for host-guest chemistry (Figure 3) and is espe-
cially well equipped to engage in multivalent interactions.
At the same time, one of the first proposed applications of
dendrimers was as container compounds, wherein small
substrates are bound within the internal voids of the den-
drimer [29]. Experimental evidence for unimolecular mi-
celle properties was established many years ago both in
hyperbranched polymers [30] and dendrimers [31].
Synthesis
Dendrimers are just in between molecular chemistry and
polymer chemistry. They relate to the molecular chemis-
try world by virtue of their step-by-step controlled syn-
thesis, and they relate to the polymer world because of
their repetitive structure made of monomers [32-35].
The three traditional macromolecular architectural clas-
ses (i.e., linear, cross-linked, and branched) are broadly
recognized to generate rather polydisperse products of
different molecular weights. In contrast, the synthesis of
dendrimers offers the chance to generate monodisperse,
structure-controlled macromolecular architectures simi-
lar to those observed in biological systems [36,37].
Dendrimers are generally prepared using either a diver-
gent method or a convergent one [38]. In the different
methods, dendrimer grows outward from a multifunc-
tional core molecule. The core molecule reacts with
monomer molecules containing one reactive and two
dormant groups, giving the first-generation dendrimer.
Then, the new periphery of the molecule is activated
for reactions with more monomers.
Cascade reactions are the foundation of dendrimer synthesis
The basic cascade or iterative methods that are currently
employed for synthesis were known to chemists muchFigure 3 Three main parts of a dendrimer: the core, end-groups, andearlier. For example, similar schemes form the basis of
solid-phase peptide synthesis. In turn, biology has long
exploited similar iterative strategies in biochemical syn-
thetic pathways; one example is provided by fatty acid
biosynthesis [39] (Figure 4).The synthesis of dendrimers follows either a divergent or
convergent approach
Dendrimers can be synthesized by two major approaches.
In the divergent approach, used in early periods, the syn-
thesis starts from the core of the dendrimer to which the
arms are attached by adding building blocks in an ex-
haustive and step-wise manner. In the convergent ap-
proach, synthesis starts from the exterior, beginning with
the molecular structure that ultimately becomes the
outermost arm of the final dendrimer. In this strategy, the
final generation number is pre-determined, necessitating
the synthesis of branches of a variety of requisite sizes be-
forehand for each generation [41] (Figure 5).Properties of dendrimers
When comparing dendrimers with other nanoscale syn-
thetic structures (e.g., traditional polymers, buck balls, or
carbon nanotubes), these are either highly non-defined or
have limited structural diversity.Pharmacokinetic properties
Pharmacokinetic properties are one of the most significant
aspects that need to be considered for the successful bio-
medical application of dendrimers, for instance, drug de-
livery, imaging, photodynamic therapy, and neutron
capture therapy. The diversity of potential applications
of dendrimers in medicine results in increasing interest
in this area. For example, there are several modifica-
tions of dendrimers' peripheral groups which enable to
obtain antibody-dendrimer, peptide-dendrimer conjugates
or dendritic boxes that encapsulate guest molecules [42].subunits linking the two molecules.
Figure 4 Cascade reaction sequences developed for the synthesis of ‘non-skid-chain like’ polyazamacrocyclic compounds [40].
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The strategy of coupling small molecules to polymeric
scaffolds by covalent linkages to improve their pharmaco-
logical properties has been under experimental test for
over three decades [43-46]. In most cases, however, the
conjugated dendritic assembly functions as ‘pro-drug’
where, upon internalization into the target cell, the conju-
gate must be liberated to activate the drug (Figure 6).
Polyvalency
Polyvalency is useful as it provides for versatile functio-
nalization; it is also extremely important to produce
multiple interactions with biological receptor sites, for
example, in the design of antiviral therapeutic agents.
Self-assembling dendrimers
Another fascinating and rapidly developing area of
chemistry is that of self-assembly. Self-assembly is the
spontaneous, precise association of chemical species by
specific, complementary intermolecular forces. Recently,
the self-assembly of dendritic structures has been of in-
creasing interest [47]. Because dendrimers contain threeA B
Figure 5 Approaches for the synthesis if dendrimers. (A) Divergent ap
dendrimers using ammonia as the trivalent core; the generations are adde
increase in the number of surface functional groups [37]. (B) Convergent a
become the periphery of the dendrimer when coupled to a multivalent codistinct structural parts (the core, end-groups, and
branched units connecting the core and periphery),
there are three strategies for self-assembling dendrimers.
The first is to create dendrons with a core unit that is cap-
able of recognizing itself or a ditopic or polytopic core
structure, therefore leading to spontaneous formation of a
dendrimer [48-51]. A self-assembling dendrimer using
pseudorotaxane formation as the organizing force was re-
ported by Gibson and coworkers (Figure 7) [52].Electrostatic interactions
Molecular recognition events at dendrimer surfaces are
distinguished by the large number of often identical
end-groups presented by the dendritic host. When
these groups are charged, the surface may have as a
polyelectrolyte and is likely to electrostatically attract
oppositely charged molecules [53]. One example of elec-
trostatic interactions between polyelectrolyte dendrimers
and charged species include the aggregation of methy-
lene blue on the dendrimer surface and the binding of
EPR probes such as copper complexes and nitroxide
cation radicals [54,55].proach: synthesis of radially symmetric polyamidoamine (PAMAM)
d at each synthetic cycle (two steps), leading to an exponential
pproach: synthesis of dendrons or wedges or branches that will
re in the last step of the synthesis [13].
Figure 6 Requirements for dendrimer-based, cancer-targeted drug delivery. (A) Dendrimers with multiple surface functional groups can be
directed to cancer cells by tumor-targeting entities that include folate or antibodies specific for tumor-associated antigens (TAAs). (B) The next
step is ingestion into the cell which, in the case of folate targeting, occurs by membrane receptor-mediated endocytosis. (C) Once inside the cell,
the drug generally must be released from the dendrimer, which, for the self-immolative method, results in the simultaneous disintegration of the
dendritic scaffold (D).
Abbasi et al. Nanoscale Research Letters 2014, 9:247 Page 5 of 10
http://www.nanoscalereslett.com/content/9/1/247Applications
Today, dendrimers have several medicinal and practical
applications.
Dendrimers in biomedical field
Dendritic polymers have advantage in biomedical applica-
tions. These dendritic polymers are analogous to protein,
enzymes, and viruses, and are easily functionalized. Dendri-
mers and other molecules can either be attached to the per-
iphery or can be encapsulated in their interior voids [56].
Modern medicine uses a variety of this material as potential
blood substitutes, e.g., polyamidoamine dendrimers [57].
Anticancer drugs
Perhaps the most promising potential of dendrimers is
in their possibility to perform controlled and specified
drug delivery, which regards the topic of nanomedicine.
One of the most fundamental problems that are set to-
ward modern medicine is to improve pharmacokinetic
properties of drugs for cancer [58]. Drugs conjugated
with polymers are characterized by lengthened half-life,higher stability, water solubility, decreased immunogen-
icity, and antigenicity [59]. Unique pathophysiological
traits of tumors such as extensive angiogenesis resulting
in hypervascularization, the increased permeability of
tumor vasculature, and limited lymphatic drainage enable
passive targeting, and as a result, selective accumulation
of macromolecules in tumor tissue. This phenomenon is
known as ‘enhanced permeation and retention’ (EPR)
[58,60]. The drug-dendrimer conjugates show high solu-
bility, reduced systemic toxicity, and selective accumula-
tion in solid tumors. Different strategies have been
proposed to enclose within the dendrimer structure drug
molecules, genetic materials, targeting agents, and dyes ei-
ther by encapsulation, complexation, or conjugation.
Dendrimers in drug delivery
In 1982, Maciejewski proposed, for the first time, the
utilization of these highly branched molecules as molecular
containers [61]. Host-guest properties of dendritic poly-
mers are currently under scientific investigation and have
gained crucial position in the field of supramolecular
Figure 7 Gibson's self-assembling dendrimers using pseudorotaxane formation. (A) Crown ethers with dendritic substituents.
(B) Triammonium ion core. (C) Schematic of tridendron formed by triple pseudorotaxane self-assembly.
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binding of a substrate molecule (guest) to a receptor mol-
ecule (host) [62].
Transdermal drug delivery
Clinical use of NSAIDs is limited due to adverse reac-
tions such as GI side effects and renal side effects when
given orally. Transdermal drug delivery overcomes these
bad effects and also maintains therapeutic blood level
for longer period of time. Transdermal delivery suffers
poor rates of transcutaneous delivery due to barrier
function of the skin. Dendrimers have found applications
in transdermal drug delivery systems. Generally, in bio-
active drugs having hydrophobic moieties in their struc-
ture and low water solubility, dendrimers are a good
choice in the field of efficient delivery system [63].
Gene delivery
The primary promise that the combination of understand-
ing molecular pathways of disease and the complete hu-
man genome sequence would yield safer and more
efficient medicines and revolutionize the way we treat
patients has not been fulfilled to date. However, there is
little doubt that genetic therapies will make a significant
contribution to our therapeutic armamentarium once
some of the key challenges, such as specific and efficientdelivery, have been solved [64]. The ability to deliver
pieces of DNA to the required parts of a cell includes
many challenges. Current research is being performed to
find ways to use dendrimers to traffic genes into cells
without damaging or deactivating the DNA. To maintain
the activity of DNA during dehydration, the dendrimer/
DNA complexes were encapsulated in a water soluble
polymer and then deposited on or sandwiched in func-
tional polymer films with a fast degradation rate to
mediate gene transfection. Based on this method,
PAMAM dendrimer/DNA complexes were used to en-
capsulate functional biodegradable polymer films for
substrate-mediated gene delivery. Research has shown
that the fast-degrading functional polymer has great
potential for localized transfection [65-67].
Dendrimers as magnetic resonance imaging contrast agents
Dendrimer-based metal chelates act as magnetic reson-
ance imaging contrast agents. Dendrimers are extremely
appropriate and used as image contrast media because
of their properties [56].
Dendritic sensors
Dendrimers, although are single molecules, can contain
high numbers of functional groups on their surfaces.
This makes them striking for applications where the
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of species is important. Balzani and coworkers investi-
gated the fluorescence of a fourth-generation poly (pro-
pylene amine) dendrimer decorated with 32 dansyl
units at the periphery (Figure 8) [68]. Since the dendri-
mer contains 30 aliphatic amine units in the interior,
suitable metal ions are able to coordinate. It was ob-
served that when a Co2+ ion is incorporated into the
dendrimer, the strong fluorescence of all the dansyl
units is quenched. Low concentrations of Co2+ ions (4.6 ×
10−7 M) can be detected using a dendrimer concentration
of 4.6 × 10−6 M. The many fluorescent groups on the sur-
face serve to amplify the sensitivity of the dendrimer as a
sensor [69].
Dendrimers used for enhancing solubility
PAMAM dendrimers are expected to have potential appli-
cations in enhancing solubility for drug delivery systems.Figure 8 Poly (propylene amine) dendrimer, containing 32 dansyl uniDendrimers have hydrophilic exteriors and interiors,
which are responsible for its unimolecular micelle nature.
Dendrimer-based carriers offer the opportunity to en-
hance the oral bioavailability of problematic drugs. Thus,
dendrimer nano carriers offer the potential to enhance the
bioavailability of drugs that are poorly soluble and/or sub-
strates for efflux transporters [70,71].
Photodynamic therapy
Photodynamic therapy (PDT) relies on the activation of
a photosensitizing agent with visible or near-infrared
(NIR) light. Upon excitation, a highly energetic state is
formed which, upon reaction with oxygen, affords a
highly reactive singlet oxygen capable of inducing necro-
sis and apoptosis in tumor cells. Dendritic delivery of
PDT agents has been investigated within the last few
years in order to improve upon tumor selectivity, reten-
tion, and pharmacokinetics [72-75].ts at its periphery.
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Clearly, there are many other areas of biological chemis-
try where application of dendrimer systems may be help-
ful. Cellular delivery using carrier dendritic polymers is
used in the purification of water dendrimer-based prod-
uct in cosmetics contaminated by toxic metal ion and
inorganic solute, and dendrimer-based commercial prod-
ucts organic solutes [76]. Furthermore, highly sensitive
analytical devices [77,78], MRI contrast agents [79],
prion research [80], burn treatment [81], and EPR im-
aging with spin-labeled dendrimers [82-106] are some of
the diverse areas of fascinating ongoing dendrimer re-
search that are beyond the scope of this article.
Conclusion
Dendrimers are characterized by individual features that
make them hopeful candidates for a lot of applications.
Dendrimers are highly defined artificial macromolecules,
which are characterized by a combination of a high num-
ber of functional groups and a compact molecular struc-
ture. A rapid increase of importance in the chemistry of
dendrimers has been observed since the first dendrimers
were prepared. Work was established to determine the
methods of preparing and investigating the properties of
the novel class of macro and micromolecules. In spite of
the two decades since the finding of dendrimers, the
multi-step synthesis still requires great effort.
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